Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering's Zocor/Zetia fixed-dose combo is likely to have coverage in one of the top two tiers in up to 50% of managed care plans six to 12 months post-launch, a Prudential survey finds. Crestor has coverage in top two tiers for about 30% of plans after one year on the market.
You may also be interested in...
Vytorin Captures 2% Of New Prescriptions In Cholesterol Market
Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.
Vytorin Captures 2% Of New Prescriptions In Cholesterol Market
Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.
Merck/Schering's Vytorin Priced At 22% Discount To Pfizer's Lipitor
The ezetimibe/simvastatin combination is priced at a 39% discount to the three highest doses of Merck's Zocor. Vytorin will launch in August at a wholesale acquisition cost of $2.34 per day.